Home > Investor Relations > Reports & Downloads > Development Pipeline

Development Pipeline

Oncology

Development code
(Compound number)
Indication
# Additional
indication
Stage
(Date)
Generic name
Product name
Dosage form
Origin
Overseas name
(Collaborator)
Mode of Action
RG435
(RO4876646)
Cervical Cancer # Approved
(16/05)
bevacizumab
Avastin®
Injection
Roche
Avastin®
Anti-VEGF (Vascular Endothelial Growth Factor) humanized monoclonal antibody
Renal cell carcinoma # Phase III
Multinational study
Malignant pleural mesothelioma # Phase II
AF802/RG7853
(CH5424802/
RO5424802)
Non-small cell lung cancer (NSCLC) [post-crizotinib] Filed
(15/09)
Europe
alectinib
Alecensa®
Oral
In-house
Alecensa®
(Roche)
ALK inhibitor
NSCLC [1st line] # Phase III
Overseas
RG1273
(RO4368451)
Breast cancer (adjuvant) # Phase III
Multinational study
pertuzumab
Perjeta®
Injection
Roche
Perjeta®
HER2 dimerization inhibitory humanized monoclonal antibody
Gastric cancer # Phase III
Multinational study
RG3502
(RO5304020)
Breast cancer (adjuvant) # Phase III
Multinational study
trastuzumab emtansine
Kadcyla®
Injection
Roche
Kadcyla®
Anti-HER2 antibody-tubulin polymerization inhibitor conjugate
GA101/RG7159
(RO5072759)
Indolent non-Hodgkin’s lymphoma (NHL) Phase III
Multinational study
obinutuzumab
 
Injection
Roche
Gazyva®/
Gazyvaro® (EU)
(Nippon Shinyaku)
Glycoengineered type II anti-CD20 monoclonal antibody
Aggressive NHL Development
discontinued
RG7446
(MPDL3280A)
NSCLC Phase III
Multinational study
atezolizumab

Injection
Roche
Tecentriq®
Engineered anti-PDL1 monoclonal antibody
NSCLC (adjuvant) Phase III
Multinational study
Small cell lung cancer (SCLC) Phase III
Multinational study
Urothelial carcinoma Phase III
Multinational study
Muscle invasive urothelial carcinoma (adjuvant) Phase III
Multinational study
Renal cell carcinoma Phase III
Multinational study
Breast cancer Phase III
Multinational study
GC33/RG7686
(GC33/
RO5137382)
Hepatocellular carcinoma Phase I
Multinational study*
codrituzumab
 
Injection
In-house

(Roche)
Anti-Glypican-3 humanized monoclonal antibody
CKI27/RG7304
(RO5126766)
Solid tumors Phase I

Oral
In-house

(Roche)
Raf and MEK dual inhibitor
Phase I
Overseas
RG7596
(RO5541077)
NHL Phase I polatuzumab vedotin
 
Injection
Roche Anti-CD79b antibody-drug conjugate
RG7604
(GDC-0032)
Solid tumors Phase I taselisib
 
Oral
Roche PI3K inhibitor
RG7440
(GDC-0068)
Solid tumors Phase I ipatasertib

Oral
Roche/Array BioPharma AKT inhibitor
ERY974
(ERY974)
Solid tumors Phase I
Overseas


Injection
In-house Anti-Glypican-3/CD3 bispecific antibody
RG6078
(GDC-0919)
Solid tumors Phase I

Oral
Roche/NewLink Genetics IDO inhibitor

* Multinational studies managed by Chugai

Bone and Joint Diseases

Development code
(Compound number)
Indication
# Additional
indication
Stage
(Date)
Generic name
Product name
Dosage form
Origin
Overseas name
(Collaborator)
Mode of Action
ED-71
(ED-71)
Osteoporosis Phase III
China
eldecalcitol
Edirol®
Oral
In-house Activated vitamin D3 agent

Renal Diseases

Development code
(Compound number)
Indication
# Additional
indication
Stage
(Date)
Generic name
Product name
Dosage form
Origin
Overseas name
(Collaborator)
Mode of Action
EOS789
(EOS789)
Hyperphosphatemia Phase I

Oral
In-house -

Autoimmune Diseases

Development code
(Compound number)
Indication
# Additional
indication
Stage
(Date)
Generic name
Product name
Dosage form
Origin
Overseas name
(Collaborator)
Mode of Action
MRA/RG1569
(RO4877533)
Large-vessel vasculitis # Phase III tocilizumab
Actemra®
Injection
In-house
Actemra®/
RoActemra® (EU)
(Roche)
Humanized anti-human IL-6 receptor monoclonal antibody
Giant cell arteritis # Phase III
Overseas
Systemic sclerosis # Phase III
Multinational study
SA237
(SA237)
Neuromyelitis optica (NMO) Phase III
Multinational study*


Injection
In-house Anti-IL-6 receptor humanized monoclonal antibody

* Multinational studies managed by Chugai

Central Nervous System

Development code
(Compound number)
Indication
# Additional
indication
Stage
(Date)
Generic name
Product name
Dosage form
Origin
Overseas name
(Collaborator)
Mode of Action
RG1450
(RO4909832)
Alzheimer’s disease Phase III
Multinational study
gantenerumab

Injection
Roche/
MorphoSys
Anti-amyloid-beta human monoclonal antibody
RG7412
(RO5490255)
Alzheimer’s disease Phase I crenezumab

Injection
Roche/
AC Immune
Anti-amyloid-beta humanized monoclonal antibody
RG1662
(RO5186582)
Improvement of intellectual ability in individuals with Down syndrome Development
discontinued
basmisanil

Oral
Roche GABAAα5 receptor antagonist

Others

Development code
(Compound number)
Indication
# Additional
indication
Stage
(Date)
Generic name
Product name
Dosage form
Origin
Overseas name
(Collaborator)
Mode of Action
ACE910/RG6013
(RO5534262)
Hemophilia A
(Inhibitor)
Phase III
Multinational study
emicizumab
 
Injection
In-house

(Roche)
Anti-FIXa/FX bispecific antibody
Hemophilia A
(Non-inhibitor)
Phase III
Multinational study
RG3637
(RO5490255)
Idiopathic pulmonary fibrosis Phase II
Multinational study
lebrikizumab
 
Injection
Roche Anti-IL-13 humanized monoclonal antibody
Asthma Development discontinued
CIM331
(CIM331)
Pruritus in dialysis patients Phase II nemolizumab
 
Injection
In-house

Anti-IL-31 receptor humanized monoclonal antibody
Atopic dermatitis
[Development out-licensed to]
- Galderma (Overseas)
- Maruho (Japan)
Phase II
Multinational study*
URC102
(URC102)
Gout Phase II
Overseas
 
 
Oral
In-house/
JW Pharmaceutical

(JW Pharmaceutical)
URAT1 inhibitor
PCO371
(PCO371)
Hypoparathyroidism Phase I
Overseas
 
 
Oral
In-house PTH1 receptor agonist

* Multinational studies managed by Chugai

In principle, completion of first dose is regarded as the start of clinical studies in each phase.

To view PDF files,
you will need Adobe® Reader® which is available as a free download.